Medical Economics January 20, 2025
Richard Payerchin

Key Takeaways

  • The Medicare Part D Drug Price Negotiation Program aims to lower drug costs, but concerns exist about its impact on beneficiaries and drug innovation.
  • Critics argue the program benefits the federal government more than Medicare beneficiaries, lacking mechanisms to pass savings to patients.
  • Concerns about transparency and potential utilization management abuse have been raised, with calls for CMS to ensure patient access and cost-savings.
  • The program’s future and effectiveness in delivering lower drug prices remain uncertain, especially under different political administrations.

Democrats claim credit, vow to fight against repeal; patient advocacy group offers critique.

The Medicare Part D Drug Price Negotiation Program generally earned praise upon releasing the latest list of 15 drugs that will be...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Congress / White House, Govt Agencies, HHS, Insurance, Medicare, Pharma, Pharma / Biotech
Medicare Drug Coverage Is Often Inadequate—Here’s Why
Medicare Drug Price Negotiations: Who really benefits?
CMS Announces Selected Drugs for 2027 Maximum Fair Price Negotiations; New Administration Issues Executive Order Affecting the IRA - Then Clarifies
GOP calls for $1.5T in cuts, much of which could come from healthcare
Payers contend with Inflation Reduction Act changes: 4 notes

Share This Article